A detailed history of Quent Capital, LLC transactions in Citius Pharmaceuticals, Inc. stock. As of the latest transaction made, Quent Capital, LLC holds 2,752 shares of CTXR stock, worth $7,072. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,752
Previous 2,752 -0.0%
Holding current value
$7,072
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jun 14, 2024

BUY
$0.65 - $0.86 $66 - $87
102 Added 3.85%
2,752 $2,000
Q4 2023

Jan 19, 2024

BUY
$0.65 - $0.86 $66 - $87
102 Added 3.85%
2,752 $2,000
Q3 2023

Jun 14, 2024

BUY
$0.65 - $1.25 $549 - $1,056
845 Added 46.81%
2,650 $1,000
Q3 2023

Oct 10, 2023

BUY
$0.65 - $1.25 $549 - $1,056
845 Added 46.81%
2,650 $1,000
Q2 2023

Jun 14, 2024

SELL
$1.08 - $1.65 $1,022 - $1,562
-947 Reduced 34.41%
1,805 $2,000
Q2 2023

Jul 10, 2023

BUY
$1.08 - $1.65 $1,949 - $2,978
1,805 New
1,805 $2,000

Others Institutions Holding CTXR

About Citius Pharmaceuticals, Inc.


  • Ticker CTXR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 146,130,000
  • Market Cap $376M
  • Description
  • Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...
More about CTXR
Track This Portfolio

Track Quent Capital, LLC Portfolio

Follow Quent Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quent Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quent Capital, LLC with notifications on news.